International Study Shows Sustained Reduction in Intraocular Pressure through Three Years with Two Glaukos iStent® Trabecular Micro-Bypass Stents in Phakic and Pseudophakic Glaucoma Patients
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a new international study, published in the November 2015 issue of Clinical Ophthalmology, showed that two iStent® Trabecular Micro-Bypass Stents provided “statistically significant, sustained and safe reduction in intraocular
